Elypta
Elypta is developing the first liquid biopsy platform based on cancer metabolism.
Total raised
€27M
€26,885,172
Funding rounds
3
Investors
9
distinct backers
Active since
2020-01
latest 2023-04
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood19
base rate 30% for Other
- ▼ Overdue vs cohort gap
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ 9y since founding
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-04-04 | Other | €888k | The Roddenberry Foundation | View deal → |
| 2022-06-20 | Series A | €20M | Bonnier Ventures,Chalmers Ventures,Hillclimber,Industrifonden,Navigare Ventures,Nina Capital+1 more | View deal → |
| 2020-01-23 | Seed | €6.0M | Industrifonden,Sciety | View deal → |
Investors
9Related news
- Vill bota cancer och backas av Norrsken – nu får Elypta 10 miljoner av Star Trek-skaparenbreakit.se · 2023-04
- Swedish biotech company grabs $21M Series A to detect early stage cancerarcticstartup.com · 2022-06
- finsmes.com